Critical Illness, Underdosing of Aminoglycosides
Conditions
Keywords
antimicrobial, intensive care units
Brief summary
This is an international observational cohort study on current aminoglycoside practices in intensive care units. Clinical and demographic data, dosing and therapeutic drug monitoring data will be collected during the first week of aminoglycoside (tobramycin, amikacin or gentamicin) administration in different countries over a year. A minimum of ten consecutive patients will be enrolled at each site.
Detailed description
Aminoglycosides are commonly used antibiotics for difficult to treat infections. However, aminoglycoside administration varies widely among countries. The aim of this multicenter observational study is to provide up-to-date and comprehensive descriptive data on current aminoglycoside (tobramycin, amikacin or gentamicin) use in a large cohort of critically ill patients in different countries. The benefits expected from this study are a better understanding of worldwide aminoglycoside prescription variability in critically ill patients and to determine the risk factors of inadequate aminoglycoside dosing regimens.
Interventions
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Intensive care unit patients * Receiving aminoglycoside therapy for a sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock
Exclusion criteria
* Aged \< 18 years of age * Previous inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aminoglycoside current practices descriptive data in intensive care units | Seven first days of aminoglycoside therapy |
Secondary
| Measure | Time frame |
|---|---|
| Aminoglycoside dosing regimens | Seven first days of aminoglycoside therapy |
| Aminoglycoside therapy duration | Seven first days of aminoglycoside therapy |
| Aminoglycoside therapeutic drug monitoring | Seven first days of aminoglycoside therapy |
Countries
Australia, Chile, France, Greece, United Kingdom
Outcome results
None listed